ALEPH-2, a suspected anxiolytic and putative hallucinogenic phenylisopropylamine derivative, is a 5-HT2a and 5-HT2c receptor agonist

被引：4

作者：

Acuña-Castillo, C

Scorza, C

Reyes-Parada, M

Cassels, BK

Huidobro-Toro, JP

机构：

[1] Pontificia Univ Catolica Chile, Fac Ciencias Biol, Dept Fisiol,Ctr Regulac Celular & Patol, Inst Milenio Biol Fundamental & Aplicada, Santiago 1, Chile

[2] Inst Invest Biol Clemente Estable, Div Biol Celular, Montevideo, Uruguay

[3] Univ Santiago Chile, Fac Ciencias Med, Santiago, Chile

[4] Univ Chile, Fac Ciencias, Dept Quim, Inst Milenio Estudios Avanzados Biol Celular & Bi, Santiago, Chile

来源：

LIFE SCIENCES | 2000年 / 67卷 / 26期

关键词：

ALEPH-2; 5-hydroxytryptamine; 5-HT2A and 5-HT2C receptors; phenylisopropylamine derivatives;

D O I：

10.1016/S0024-3205(00)00906-1

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

To assess the pharmacodynamic profile of ALEPH-2, a phenylisopropylamine derivative with alleged anxiolytic and hallucinogenic properties,Xenopus laevis oocytes were microinjected with either of the rat cRNA for the 5-HT2A or the 5-HT2C receptor. Concentration-response curves were obtained following the exposure of the oocytes to varying concentrations of either ALEPH-2 or 5-hydroxy-tryptamine (5-HT) for 10 s. ALEPH-2 is a partial agonist on the 5-HT,,receptor with a similar potency to 5-HT. In contrast, ALEPH-2 is a full 5-HT2C receptor agonist and is about 15-fold less potent than 5-HT. Pre-application of 1 muM ritanserin antagonized the responses induced by 5-HT and ALEPH-2 to the same extent; however, the 5-HT2A receptor is more sensitive to ritanserin blockade than the 5-HT2C receptor. (C) 2000 Elsevier Science Inc. All rights reserved.

引用

页码：3241 / 3247

页数：7

共 50 条

[41] 5-HT1A and 5-HT2A Signaling, Desensitization, and Downregulation: Serotonergic Dysfunction and Abnormal Receptor Density in Schizophrenia and the Prodrome [J].

Kim, Sun A. .

CUREUS JOURNAL OF MEDICAL SCIENCE, 2021, 13 (06)

[42] Antiplatelet and antithrombotic activity of SL65.0472, a mixed 5-HT1B/5-HT2A receptor antagonist [J].

Berry, CN ;

Lorrain, J ;

Lochot, S ;

Delahaye, M ;

Lalé, A ;

Savi, P ;

Lechaire, I ;

Ferrari, P ;

Bernat, A ;

Schaeffer, P ;

Janiak, P ;

Duval, N ;

Grosset, A ;

Herbert, JM ;

O'Connor, SE .

THROMBOSIS AND HAEMOSTASIS, 2001, 85 (03) :521-528

[43] Citalopram-induced hypophagia is enhanced by blockade of 5-HT1A receptors:: Role of 5-HT2C receptors [J].

Grignaschi, G ;

Invernizzi, RW ;

Fanelli, E ;

Fracasso, C ;

Caccia, S ;

Samanin, R .

BRITISH JOURNAL OF PHARMACOLOGY, 1998, 124 (08) :1781-1787

[44] 3-Substituted 1-methyl-3-benzazepin-2-ones as 5-HT2C receptor agonists [J].

Shidore, Mahesh ;

Machhi, Jatin ;

Murumkar, Prashant ;

Barmade, Mahesh ;

Thanki, Jigar ;

Yadav, Mange Ram .

RSC ADVANCES, 2015, 5 (111) :91908-91921

[45] 5-HT2A receptor dysregulation in a schizophrenia relevant mouse model of NMDA receptor hypofunction [J].

Nakao, Kazuhito ;

Singh, Mahendra ;

Sapkota, Kiran ;

Fitzgerald, Andrew ;

Hablitz, John J. ;

Nakazawa, Kazu .

TRANSLATIONAL PSYCHIATRY, 2022, 12 (01)

[46] The effects of the 5-HT2C agonist m-chlorophenylpiperazine on elite athletes with unexplained underperformance syndrome (overtraining) [J].

Budgett, R. ;

Hiscock, N. ;

Arida, R. ;

Castell, L. M. .

BRITISH JOURNAL OF SPORTS MEDICINE, 2010, 44 (04) :280-U24

[47] Similarities in the action of Ro 60-0175, a 5-HT2C receptor agonist, and d-fenfluramine on feeding patterns in the rat [J].

Clifton, PG ;

Lee, MD ;

Dourish, CT .

PSYCHOPHARMACOLOGY, 2000, 152 (03) :256-267

[48] 5-HT2A receptor enhancement of contractile activity of the porcine urothelium and lamina propria [J].

Moro, Christian ;

Edwards, Lily ;

Chess-Williams, Russ .

INTERNATIONAL JOURNAL OF UROLOGY, 2016, 23 (11) :946-951

[49] Interaction of ergovaline with serotonin receptor 5-HT2A in bovine ruminal and mesenteric vasculaturel [J].

Trotta, Ronald J. ;

Harmon, David L. ;

Klotz, James L. .

JOURNAL OF ANIMAL SCIENCE, 2018, 96 (11) :4912-4922

[50] The 5-HT1A and 5-HT2A/2C receptor antagonists WAY-100635 and ritanserin do not attenuate D-fenfluramine-induced Fos expression in the brain [J].

Javed, A ;

Van de Kar, LD ;

Gray, TS .

BRAIN RESEARCH, 1998, 791 (1-2) :67-74

← 1 2 3 4 5 →